133 related articles for article (PubMed ID: 21410345)
1. Basal phenotype breast cancer: implications for treatment and prognosis.
Pazaiti A; Fentiman IS
Womens Health (Lond); 2011 Mar; 7(2):181-202. PubMed ID: 21410345
[TBL] [Abstract][Full Text] [Related]
2. Molecular insights on basal-like breast cancer.
Valentin MD; da Silva SD; Privat M; Alaoui-Jamali M; Bignon YJ
Breast Cancer Res Treat; 2012 Jul; 134(1):21-30. PubMed ID: 22234518
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
4. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Rakha EA; Elsheikh SE; Aleskandarany MA; Habashi HO; Green AR; Powe DG; El-Sayed ME; Benhasouna A; Brunet JS; Akslen LA; Evans AJ; Blamey R; Reis-Filho JS; Foulkes WD; Ellis IO
Clin Cancer Res; 2009 Apr; 15(7):2302-10. PubMed ID: 19318481
[TBL] [Abstract][Full Text] [Related]
6. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic characteristics of breast cancer with basal-like immunophenotype].
Wu WX; Han WL; Zhang YP; Yu QX; Wen XW; Lu N; Tang ZY; Yuan LN; Zhang Y; Wang Z; Wang W; Yang HJ; Chen CP; Guo WL
Zhonghua Bing Li Xue Za Zhi; 2008 Nov; 37(11):743-8. PubMed ID: 19094708
[TBL] [Abstract][Full Text] [Related]
9. What is the difference between triple-negative and basal breast cancers?
Seal MD; Chia SK
Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
[TBL] [Abstract][Full Text] [Related]
10. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer.
Li CI; Zhang Y; Cieślik M; Wu YM; Xiao L; Cobain E; Tang MC; Cao X; Porter P; Guenthoer J; Robinson DR; Chinnaiyan AM
Clin Cancer Res; 2021 Jun; 27(11):3079-3093. PubMed ID: 33753452
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay.
Jensen TW; Ray T; Wang J; Li X; Naritoku WY; Han B; Bellafiore F; Bagaria SP; Qu A; Cui X; Taylor CR; Ray PS
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26041837
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
14. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
15. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
16. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
17. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
Huber KE; Carey LA; Wazer DE
Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
[TBL] [Abstract][Full Text] [Related]
19. Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features.
Leidy J; Khan A; Kandil D
Arch Pathol Lab Med; 2014 Jan; 138(1):37-43. PubMed ID: 24377810
[TBL] [Abstract][Full Text] [Related]
20. Triple-Negative Breast Carcinoma.
Livasy CA
Surg Pathol Clin; 2009 Jun; 2(2):247-61. PubMed ID: 26838321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
